Kuldeepak Sharma, PhD
Dr. Kuldeepak Sharma
Kuldeepak Sharma, PhD, is a pharmaceutical consultant with twenty years of experience in research, clinical trials, business, patent and product development including: new process & technology development; clinical, project leadership; project planning; project management; patent research; managing research, design and engineering (R,D&E) groups. Dr. Sharma is organized, innovative and entrepreneurial. He is the inventor of ten US patents (four filed, six issued) and has authored about 12 journal papers and 3 book review chapters. Dr. Sharma has developed a unique drug / technology selection model for various drug delivery platforms. Dr. Sharma has successfully transferred the complex drug delivery technology from Japan to USA. A local company has used this model in technology selection and saved about 900K dollars with the help of this model. (This is me - Update Profile)
| 2003 - present | President/Pharmaceutical Consultant Dr. Kuldeepak Sharma |
|---|
GLG Study Groups with Kuldeepak Sharma, PhD(?)
| Study Group Name | Members |
|---|---|
| Opana ER Prescribers (US) | 91 |
| Prescribers of Aldara (US) | 66 |
| Medical Tourism Experts | 279 |
GLG NewsSM
Analyses by Kuldeepak Sharma, PhD(?)
As a pharmaceutical consultant working in pain management area, I think lower dose will offer similar efficacy as Soma 350 mg but with a more favorable tolerability profile. Last week, Last week, The Food and Drug Administration (FDA) have approved 250 mg (lower dose) of Soma (carisoprodol) for treatment...
Food and Drug Administration (FDA) has approved the first generic versions of Coreg (carvedilol). It is good news for patients. Coreg is a widely used medication that is FDA-approved to treat high blood pressure, mild to severe chronic heart failure and left ventricular dysfunction following...
This article is sad but consistent with overall increase use / abuse of opioids pain killers such as morphine, oxycodone, and hydrocodone. As a pharmacist & pharmaceutical consultant I think these are main reasons for alarming increase of opioids drugs use in America: The population is getting older....
The FDA has announced changes in the Warfarin label, recommending that a lower initial Warfarin dose should be considered for patients with certain genetic variations. Warfarin (Coumadin) is a commonly prescribed blood thinner with an exceptionally narrow safe-dosage range that varies dramatically from...
GLG InstituteSM Seminars with Kuldeepak Sharma, PhD(?)
Recent Seminars
Request a project with Kuldeepak Sharma, PhD
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms